Table 3. (a) Univariate and (b) multivariate analyses for the effects of GOLPH3 expression on the progression-free, cancer-specific and overall survival of 137 patients treated with radical cystectomy for urothelial carcinoma of the bladder.
| Variable | Progression Free | Cancer Specific | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | |
| (a) | |||||||||
| Gender (Male vs Female) | 0.638 | 0.345–1.180 | 0.152 | 0.585 | 0.306–1.119 | 0.105 | 0.510 | 0.283–0.918 | 0.025 |
| Age (≤65 y vs >65 y) | 1.310 | 0.793–2.163 | 0.292 | 1.598 | 0.910–2.807 | 0.103 | 1.690 | 0.994–2.876 | 0.053 |
| Grade(G1–G2 vs G3) | 2.272 | 1.218–5.235 | 0.010 | 2.093 | 1.047–4.183 | 0.037 | 2.231 | 1.154–4.314 | 0.017 |
| pT status (NMI vs MI) | 4.223 | 2.385–7.477 | < 0.001 | 4.197 | 2.230–7.900 | < 0.001 | 3.469 | 1.966–6.121 | < 0.001 |
| pN status (N0 vs N1–N2) | 6.077 | 3.306–11.173 | < 0.001 | 6.206 | 3.282–11.736 | < 0.001 | 5.715 | 3.115–10.483 | < 0.001 |
| Multiplicity (Unifocal vs Multifocal) | 1.790 | 1.056–3.035 | 0.031 | 1.343 | 0.735–2.454 | 0.338 | 1.465 | 0.840–2.557 | 0.179 |
| GOLPH3 expression (Low vs High) | 2.406 | 1.437–4.027 | 0.001 | 3.041 | 1.680–5.506 | < 0.001 | 2.631 | 1.528–4.529 | < 0.001 |
| Ki67 expression (Low vs High) | 3.379 | 1.924–5.934 | < 0.001 | 4.118 | 2.110–8.040 | < 0.001 | 3.294 | 1.827–5.940 | < 0.001 |
| Variable | Progression Free | Cancer Specfic | Overall Survival | ||||||
| HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | |
| (b) | |||||||||
| Gender (Male vs Female) | 0.644 | 0.338–1.229 | 0.183 | 0.569 | 0.286–1.131 | 0.108 | 0.484 | 0.259–0.904 | 0.023 |
| Age (≤65 y vs > 65 y) | 1.111 | 0.641–1.927 | 0.707 | 1.274 | 0.684–2.374 | 0.445 | 1.436 | 0.797–2.587 | 0.228 |
| Grade(G1-G2 vs G3) | 1.431 | 0.735–2.787 | 0.292 | 1.159 | 0.553–2.427 | 0.696 | 1.351 | 0.671–2.720 | 0.400 |
| pT status (NMI vs MI) | 2.558 | 1.370–4.777 | 0.003 | 2.424 | 1.212–4.848 | 0.012 | 1.997 | 1.065–3.745 | 0.031 |
| pN status (N0 vs N1–N2) | 3.069 | 1.543–6.107 | 0.001 | 3.364 | 1.625–6.963 | 0.001 | 3.499 | 1.731–7.071 | < 0.001 |
| Multiplicity (Unifocal vs Multifocal) | 1.370 | 0.786–2.386 | 0.267 | 1.012 | 0.538–1.904 | 0.971 | 1.192 | 1.122–3.392 | 0.557 |
| GOLPH3 expression (Low vs High) | 1.920 | 1.130–3.260 | 0.016 | 2.257 | 1.235–4.126 | 0.008 | 1.951 | 1.122–3.392 | 0.018 |
| Ki67 expression (Low vs High) | 2.337 | 1.282–4.259 | 0.006 | 2.515 | 1.239–5.107 | 0.011 | 1.951 | 1.041–3.655 | 0.037 |
HR = hazard ratio; CI = confidence interval; NMI = Non-muscle invasive bladder cancer; MI = Muscle invasive bladder cancer.